HC Wainwright Has Positive Outlook for AVTX Q1 Earnings

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Avalo Therapeutics in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($1.10) per share for the quarter, up from their prior estimate of ($1.76). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q2 2026 earnings at ($1.04) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.97) EPS, FY2026 earnings at ($4.02) EPS and FY2027 earnings at ($4.90) EPS.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million.

AVTX has been the topic of a number of other research reports. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim began coverage on shares of Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 price objective on the stock. BTIG Research reiterated a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Avalo Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $42.25.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $13.89 on Friday. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $20.72. The firm has a market capitalization of $316.55 million, a price-to-earnings ratio of -2.42 and a beta of 0.84. The business’s 50 day moving average price is $15.47 and its 200-day moving average price is $15.78.

Institutional Trading of Avalo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. PFS Partners LLC raised its holdings in shares of Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after acquiring an additional 1,000 shares during the period. BIT Capital GmbH purchased a new stake in shares of Avalo Therapeutics in the third quarter valued at about $25,000. Geode Capital Management LLC increased its position in Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in Avalo Therapeutics during the second quarter worth about $55,000. Finally, Dimensional Fund Advisors LP purchased a new position in Avalo Therapeutics during the third quarter worth about $143,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the transaction, the insider owned 3,622 shares in the company, valued at approximately $58,495.30. This trade represents a 87.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 3.03% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.